Skip to content

Efficacy of maggot therapy on Staphilococcus aureus and Pseudomonas aeruginosa in diabetic foot ulcers

A clinical trial on efficacy of maggot therapy on Staphilococcus aureus and Pseudomonas aeruginosa in diabetic foot ulcers

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016060328232N1
Enrollment
50
Registered
2017-04-02
Start date
2017-04-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic ulcer of skin, not elsewhere classified. Chronic ulcer of skin NOS

Interventions

Intervention 1: Patients in intervention group will receive maggot debridement therapy in addition with routine treatment process for healing of diabetic foot ulcers. Intervention 2: Patients in contr
Treatment - Surgery
Patients in intervention group will receive maggot debridement therapy in addition with routine treatment process for healing of diabetic foot ulcers.
Patients in control group will receive routine healing process for healing of diabetic foot ulcers.

Sponsors

Vice Chancellor of Research, Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with at least one diabetic foot ulcer, second degree (based on Wagner); Presence of at least one of two bacteria (Staphilococcus aureus and Pseudomonas aeruginosa) in the ulcers, patient's age between 30 to 80; At least seven week post ulceration; having ankle-brachial index (ABI) more than 0.6 or two clear beats on ulcerated leg; not need to be hospitalized; lack of other dangerous diseases; no need for anticoagulant or steroid pharmaceutics; ?not addicted to alcohol or opium; no entomophobia; to sign the consent. Exclusion criteria: Having sever diseases such as heart disorders and so on, Sever pain during maggot Therapy, Sever and un-controlled fever during maggot therapy, maceration around the wound after each interval of maggot therapy, Emergent hospitalization during or after of each interval of maggot therapy, Bleeding during maggot therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
?acterial infections, Staphilococcus aureus and Pseudomonas aeruginosa. Timepoint: sampling before starting of the study and 48 and 96 hours after starting of the study. Method of measurement: culturing of samples in laboratory.

Secondary

MeasureTime frame
Amounts of wound secretions. Timepoint: 48 and 96 hours after starting of the study. Method of measurement: befors/after weighing of dressings of diabetic foot ulcers of both groups, treatment and control, synchronizingly.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Masud Yunesian

Tehran University of Medical Sciences

yunesianm@yahoo.com+98 21 8163 3698

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026